Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) Return on Capital Employed: 2022-2025

Historic Return on Capital Employed for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Sep 2025 value amounting to -1.40%.

  • Phathom Pharmaceuticals' Return on Capital Employed fell 40.00% to -1.40% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.40%, marking a year-over-year decrease of 40.00%. This contributed to the annual value of -0.89% for FY2024, which is 23.00% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Return on Capital Employed stood at -1.40% for Q3 2025, which was up 5.90% from -1.49% recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Return on Capital Employed ranged from a high of -0.58% in Q4 2023 and a low of -1.49% during Q2 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.93% (2024), whereas its average is -0.97%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first surged by 57bps in 2024, then tumbled by 62bps in 2025.
  • Over the past 4 years, Phathom Pharmaceuticals' Return on Capital Employed (Quarterly) stood at -1.10% in 2022, then skyrocketed by 51bps to -0.58% in 2023, then slumped by 35bps to -0.93% in 2024, then crashed by 40bps to -1.40% in 2025.
  • Its Return on Capital Employed was -1.40% in Q3 2025, compared to -1.49% in Q2 2025 and -1.09% in Q1 2025.